Osimertinib, a third-generation EGFR inhibitor, has proven effective in the treatment of EGFR-mutated NSCLC as shown through a decreased level of p-ERK following treatment with Osimertinib. Here, MAPK1 is linked to non-small cell lung carcinoma.